N-(6-氯吡啶-3-基)乙酰胺 | 29958-18-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-(6-氯吡啶-3-基)乙酰胺
• 英文名称: 5-acetamido-2-chloropyridine
• 英文别名: N-(6-chloro-pyridin-3-yl)-acetamide；N-(6-chloro-[3]pyridyl)-acetamide；N-(6-Chlor-[3]pyridyl)-acetamid；2-Chlor-5-acetylaminopyridin；5-Acetamido-2-chlor-pyridin；N-(6-chloropyridin-3-yl)acetamide
• CAS: 29958-18-7
• 化学式: C₇H₇ClN₂O
• 分子量: 170.598
• InChiKey: XLJCAGLIVIQUIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Acetamido-2-chloropyridine
Synonyms: N-(6-Chloropyridin-3-yl)acetamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Acetamido-2-chloropyridine
CAS number: 29958-18-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H7ClN2O
Molecular weight: 170.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-(6-氯吡啶-3-基)乙酰胺 、 异丁胺 在 palladium diacetate 、 (R)-(-)-1-[(S)-2-(二环己基膦)二茂铁]乙基二叔丁基膦 lithium hexamethyldisilazane 作用下， 以 乙二醇二甲醚 为溶剂， 反应 24.0h， 以67%的产率得到5-acetamido-2-iso-butylaminopyridine
  参考文献：
  名称：

  钯催化杂芳基和芳基氯化物、溴化物和碘化物的高活性、通用和长寿命催化剂：范围和结构-活性关系

  摘要：

  我们描述了对一类高效和选择性催化剂的配体结构和活性之间的范围和关系的系统研究，该催化剂包含空间位阻螯合烷基膦，用于杂芳基和芳基氯化物、溴化物和碘化物的胺化。在这种催化剂的存在下，芳基和杂芳基氯化物、溴化物和碘化物与许多伯胺以高产率反应，并产生百万分之几的钯前体和配体。伯胺与杂芳基和芳基氯化物、溴化物和碘化物的许多反应在 0.0005-0.05 mol% 的催化剂下完成。将这种催化剂在这些负载下与伯胺偶联的反应性与由受阻单膦和卡宾生成的催化剂进行比较，这些数据说明了螯合的好处。对活性最高的催化剂结构变体的研究表明，双齿结构中的刚性主链、强电子供体和严重的阻碍都有助于其高反应性。因此，这些配合物构成了芳基卤化物胺化的第四代催化剂，其活性与基于单膦和卡宾的催化剂相辅相成。

  DOI：

  10.1021/ja077074w
• 作为产物：
  描述：

  2-氯-5-氨基吡啶 生成 N-(6-氯吡啶-3-基)乙酰胺
  参考文献：
  名称：

  Adams et al., Journal of the Chemical Society, 1949, p. 3181,3183

  摘要：

  DOI：

文献信息

• IDO INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160289171A1

  公开（公告）日：2016-10-06

  There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

  已披露的化合物可调节或抑制吲哌酮胺2,3-二氧化酶（IDO）的酶活性，含有该化合物的药物组合物以及利用本发明的化合物治疗增殖性疾病，如癌症、病毒感染和/或炎症性疾病的方法。
• HETEROCYCLIC COMPOUND
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20160159773A1

  公开（公告）日：2016-06-09

  The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种用于预防或治疗自身免疫性疾病（例如牛皮癣、类风湿关节炎、炎症性肠病、干燥综合征、贝赫切特病、多发性硬化症、系统性红斑狼疮等）等的药剂，其具有优越的Tyk2抑制作用。 本发明涉及一种由下式表示的化合物 其中每个符号如规范中定义的，或其盐。
• Acetanilide derivatives
  申请人：ZENECA LIMITED

  公开号：EP0610032A1

  公开（公告）日：1994-08-10

  The invention concerns acetanilide derivatives of the formula I wherein R⁴ is (1-4C)alkyl; R⁵ is hydrogen or (1-4C)alkyl; Ar¹ is phenylene, pyridinediyl or pyrimidinediyl; A¹ is a direct link to X¹ or A¹ is (1-4C)alkylene; X¹ is oxy, thio, sulphinyl or sulphonyl; Ar² is thiophenediyl, furandiyl, thiazolediyl, oxazolediyl, thiadiazolediyl or oxadiazolediyl; R¹ and R² together form a group of the formula -A²-X²-A³- which together with the oxygen atom to which A² is attached and with the carbon atom to which A³ is attached define a ring having 5 or 6 ring atoms, wherein each of A² and A³ is (1-3C)alkylene and X² is oxy, thio, sulphinyl or sulphonyl and which ring may bear one, two or three (1-4C)alkyl substituents; and R³ is (1-4C)alkyl; or pharmaceutically-acceptable salts thereof; processes for their manufacture; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.

  该发明涉及具有以下式I的乙酰苯胺衍生物，其中R⁴是(1-4C)烷基；R⁵是氢或(1-4C)烷基；Ar¹是苯基、吡啶二基或嘧啶二基；A¹是直接连接到X¹的链或A¹是(1-4C)烷基；X¹是氧、硫、亚砜基或砜基；Ar²是噻吩二基、呋喃二基、噻唑二基、噁唑二基、噻二唑二基或噁二唑二基；R¹和R²一起形成一个具有5或6个环原子的环的基团，其中A²和A³各自是(1-3C)烷基，X²是氧、硫、亚砜基或砜基，该环可能具有一个、两个或三个(1-4C)烷基取代基；R³是(1-4C)烷基；或其药用可接受盐；其制备方法；含有它们的药物组合物以及它们作为5-脂氧合酶抑制剂的用途。
• Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase
  申请人：Birch Martin Alan

  公开号：US20050131015A1

  公开（公告）日：2005-06-16

  Heterocyclic amides of formula (1) wherein: X is N or CH; R 4 and R 5 together are either —S—C(R 6 )═C(R 7 )— or —C(R 7 )═C(R 6 )—S—; R 6 and R 7 are independently selected from, for example hydrogen, halo and C l-4 alkyl; A is phenylene or heteroarylene; n is 0, 1 or 2; R 1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; R 2 is hydrogen, hydroxy or carboxy; R 3 is selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C 1-4 alkyl(optionally substituted by 1 or 2 R 8 groups); R 8 is selected from for example hydroxy, —COCOOR 9 , —C(O)N(R 9 )(R 10 ), —NHC(O)R 9 , (R 9 )(R 10 )N— and —COOR 9 ; R 9 and R 10 are selected from for example hydrogen, hydroxy, C 1-4 alkyl (optionally substituted by 1 or 2 R 13 ); R 13 is selected from hydroxy, halo, trihalomethyl and C 1-4 alkoxy; or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.

  公式（1）的杂环酰胺，其中：X是N或CH；R4和R5一起是—S—C(R6)═C(R7)—或—C(R7)═C(R6)—S—；R6和R7独立选择自氢、卤素和Cl-4烷基；A是苯基或杂环芳基；n为0、1或2；R1选择自卤素、硝基、氰基、羟基、羧基；R2是氢、羟基或羧基；R3选择自氢、羟基、芳基、杂环芳基和C1-4烷基（可选地取代1或2个R8基）；R8选择自羟基、—COCOOR9、—C（O）N（R9）（R10）、—NHC（O）R9、（R9）（R10）N—和—COOR9；R9和R10选择自氢、羟基、C1-4烷基（可选地取代1或2个R13）；R13选择自羟基、卤素、三卤甲基和C1-4烷氧基；或其药学上可接受的盐或前药；具有糖原磷酸化酶抑制活性，因此在治疗与增加的糖原磷酸化酶活性相关的疾病状态中具有价值。还描述了制造该杂环酰胺衍生物的过程以及含有它们的制药组合物。
• Chemical compounds
  申请人：Birch Martin Alan

  公开号：US20050131016A1

  公开（公告）日：2005-06-16

  Heterocyclic amides of formula (1) wherein: is a single or double bond; A is phenylene or heteroarylene; m is 0, 1 or 2; n is 0, 1 or 2; R 1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; R 2 is hydrogen, hydroxy or carboxy; R 3 is selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C 1-4 alkyl(optionally substituted by 1 or 2 R 8 groups); R 4 is independently selected from for example hydrogen, halo, nitro, cyano, hydroxy, C 1-4 alkyl, and C 1-4 alkanoyl; R 8 is selected from for example hydroxy, —COCOOR 9 , —C(O)N(R 9 )(R 10 ), —NHC(O)R 9 , (R 9 )(R 10 )N— and —COOR 9 ; R 9 and R 10 are selected from for example hydrogen, hydroxy, C 1-4 alkyl (optionally substituted by 1 or 2 R 13 ); R 13 is selected from hydroxy, halo, trihalomethyl and C 1-4 alkoxy; or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.

  化学式（1）中的杂环酰胺，其中：为单键或双键；A为苯基或杂环基；m为0、1或2；n为0、1或2；R1选自例如卤素、硝基、氰基、羟基、羧基；R2为氢、羟基或羧基；R3选自例如氢、羟基、芳基、杂环基和C1-4烷基（可选地被1或2个R8基取代）；R4独立选自例如氢、卤素、硝基、氰基、羟基、C1-4烷基和C1-4烷酰基；R8选自例如羟基、—COCOOR9、—C（O）N（R9）（R10）、—NHC（O）R9、（R9）（R10）N—和—COOR9；R9和R10选自例如氢、羟基、C1-4烷基（可选地被1或2个R13取代）；R13选自羟基、卤素、三卤甲基和C1-4烷氧基；或其药学上可接受的盐或前药；具有糖原磷酸化酶抑制活性，因此对治疗与增加的糖原磷酸化酶活性相关的疾病状态具有价值。描述了制备所述杂环酰胺衍生物的工艺和含有它们的药物组成物。